When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
DCPH - Deciphera's Qinlock OK'd in Australia for fourth-line gastrointestinal stromal tumor
Deciphera Pharmaceuticals Inc.
The Australian Therapeutic Goods Administration has approved Deciphera Pharmaceuticals' (NASDAQ:DCPH) QINLOCK (ripretinib), a switch-control tyrosine kinase inhibitor, for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib.
More news on: Deciphera Pharmaceuticals, Inc., Healthcare stocks news,